Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Teijin Still Seeking “Best Owner” for Legacy Drug Portfolio
Teijin remains on the hunt for the “best owner” of eight legacy prescription drugs, including the DPP-4 inhibitor Nesina (alogliptin) and three other diabetes medicines, as it restructures its pharmaceutical business around rare and intractable diseases. At an earnings briefing…
To read the full story
Related Article
- Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
June 18, 2026
- Teijin to Offload Legacy Drug Portfolio as It Speeds Up Pivot to Rare Diseases
May 12, 2026
- Teijin Slashes FY2025 Forecast on Pharma Impairment
April 2, 2026
- Teijin Debuts Yorvipath in Japan, Eyes Rare Disease Growth
November 7, 2025
- Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
- Teijin Earns Japan Rights to 3 Hormone Therapies from Denmark’s Ascendis
November 30, 2023
- Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
March 15, 2023
BUSINESS
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
- AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
August 5, 2026
- Voyxact PIII Data Confirm Kidney Function Stabilization in IgAN
August 5, 2026
- Perioperative Imfinzi Seen Advancing Gastric Cancer Care: Oncologist
August 5, 2026
- Teijin Still Seeking “Best Owner” for Legacy Drug Portfolio
August 5, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…